How imiquimod licenses plasmacytoid dendritic cells to kill tumors

We have provided evidence for a multifaceted antitumor-function of the Toll-like receptor 7 (TLR7) agonist imiquimod, which rapidly recruits plasmacytoid dendritic cells and possibly other immune cells into tumors by inducing the secretion of CCL2 by dermal cells. Imiquimod induces pDC maturation an...

Descripción completa

Detalles Bibliográficos
Autores principales: Holcmann, Martin, Drobits, Barbara, Sibilia, Maria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2012
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3525638/
https://www.ncbi.nlm.nih.gov/pubmed/23264929
http://dx.doi.org/10.4161/onci.22033
Descripción
Sumario:We have provided evidence for a multifaceted antitumor-function of the Toll-like receptor 7 (TLR7) agonist imiquimod, which rapidly recruits plasmacytoid dendritic cells and possibly other immune cells into tumors by inducing the secretion of CCL2 by dermal cells. Imiquimod induces pDC maturation and their conversion into cytolytic killer cells, which are capable of eliminating tumors independently from the adaptive immune system.

Ejemplares similares